Cargando…
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past 20 years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, organ toxicity, and graft-versus-host disease. We hypot...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168504/ https://www.ncbi.nlm.nih.gov/pubmed/32499241 http://dx.doi.org/10.3324/haematol.2020.248187 |
_version_ | 1783701891016818688 |
---|---|
author | Cooper, Jason P. Storer, Barry E. Granot, Noa Gyurkocza, Boglarka Sorror, Mohamed L. Chauncey, Thomas R. Shizuru, Judith Franke, Georg-Nikolaus Maris, Michael B. Boyer, Michael Bruno, Benedetto Sahebi, Firoozeh Langston, Amelia A. Hari, Parameswaran Agura, Edward D. Petersen, Søren Lykke Maziarz, Richard T. Bethge, Wolfgang Asch, Julie Gutman, Jonathan A. Olesen, Gitte Yeager, Andrew M. Hübel, Kai Hogan, William J. Maloney, David G. Mielcarek, Marco Martin, Paul J. Flowers, Mary E. D. Georges, George E. Woolfrey, Ann E. Deeg, H. Joachim Scott, Bart L. McDonald, George B. Storb, Rainer Sandmaier, Brenda M. |
author_facet | Cooper, Jason P. Storer, Barry E. Granot, Noa Gyurkocza, Boglarka Sorror, Mohamed L. Chauncey, Thomas R. Shizuru, Judith Franke, Georg-Nikolaus Maris, Michael B. Boyer, Michael Bruno, Benedetto Sahebi, Firoozeh Langston, Amelia A. Hari, Parameswaran Agura, Edward D. Petersen, Søren Lykke Maziarz, Richard T. Bethge, Wolfgang Asch, Julie Gutman, Jonathan A. Olesen, Gitte Yeager, Andrew M. Hübel, Kai Hogan, William J. Maloney, David G. Mielcarek, Marco Martin, Paul J. Flowers, Mary E. D. Georges, George E. Woolfrey, Ann E. Deeg, H. Joachim Scott, Bart L. McDonald, George B. Storb, Rainer Sandmaier, Brenda M. |
author_sort | Cooper, Jason P. |
collection | PubMed |
description | We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past 20 years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, organ toxicity, and graft-versus-host disease. We hypothesized that improvements in clinical practice led to better transplantation outcomes over time. From 1997–2017, 1,720 patients with hematologic malignancies received low-dose total body irradiation ± fludarabine or clofarabine before transplantation from HLAmatched sibling or unrelated donors, followed by mycophenolate mofetil and a calcineurin inhibitor ± sirolimus. We compared outcomes in three cohorts by year of transplantation: 1997–2003 (n=562), 2004–2009 (n =594), and 2010–2017 (n=564). The proportion of patients ≥60 years old increased from 27% in 1997–2003 to 56% in 2010–2017, and with scores from the Hematopoietic Cell Transplantation Comorbidity Index of ≥3 increased from 25% in 1997–2003 to 45% in 2010–2017. Use of unrelated donors increased from 34% in 1997–2003 to 65% in 2010–2017. When outcomes from 2004–2009 and 2010–2017 were compared to 1997–2003, improvements were noted in overall survival (P=0.0001 for 2004–2009 and P≤0.0001 for 2010–2017), progression-free survival (P=0.002 for 2004–2009 and P<0.0001 for 2010–2017), non-relapse mortality (P<0.0001 for 2004– 2009 and P<0.0001 for 2010–2017), and in rates of grades 2–4 acute and chronic graft-versus-host disease. For patients with hematologic malignancies who underwent transplantation with non-myeloablative conditioning, outcomes have improved during the past two decades. Trials reported are registered under clinicaltrials gov. Identifiers: NCT00003145, NCT00003196, 005803, NCT00006251, NCT00014235, NCT00027820, NCT00031655, NCT00036738, NCT00045435, NCT00052546, NCT00060424, NCT00075478, NCT00078858, NCT00089011, NCT00104858, NCT00105001, NCT00110058, NCT00397813, NCT00793572, NCT01231412, NCT01252667, NCT01527045. |
format | Online Article Text |
id | pubmed-8168504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Fondazione Ferrata Storti |
record_format | MEDLINE/PubMed |
spelling | pubmed-81685042021-06-11 Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades Cooper, Jason P. Storer, Barry E. Granot, Noa Gyurkocza, Boglarka Sorror, Mohamed L. Chauncey, Thomas R. Shizuru, Judith Franke, Georg-Nikolaus Maris, Michael B. Boyer, Michael Bruno, Benedetto Sahebi, Firoozeh Langston, Amelia A. Hari, Parameswaran Agura, Edward D. Petersen, Søren Lykke Maziarz, Richard T. Bethge, Wolfgang Asch, Julie Gutman, Jonathan A. Olesen, Gitte Yeager, Andrew M. Hübel, Kai Hogan, William J. Maloney, David G. Mielcarek, Marco Martin, Paul J. Flowers, Mary E. D. Georges, George E. Woolfrey, Ann E. Deeg, H. Joachim Scott, Bart L. McDonald, George B. Storb, Rainer Sandmaier, Brenda M. Haematologica Article We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past 20 years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, organ toxicity, and graft-versus-host disease. We hypothesized that improvements in clinical practice led to better transplantation outcomes over time. From 1997–2017, 1,720 patients with hematologic malignancies received low-dose total body irradiation ± fludarabine or clofarabine before transplantation from HLAmatched sibling or unrelated donors, followed by mycophenolate mofetil and a calcineurin inhibitor ± sirolimus. We compared outcomes in three cohorts by year of transplantation: 1997–2003 (n=562), 2004–2009 (n =594), and 2010–2017 (n=564). The proportion of patients ≥60 years old increased from 27% in 1997–2003 to 56% in 2010–2017, and with scores from the Hematopoietic Cell Transplantation Comorbidity Index of ≥3 increased from 25% in 1997–2003 to 45% in 2010–2017. Use of unrelated donors increased from 34% in 1997–2003 to 65% in 2010–2017. When outcomes from 2004–2009 and 2010–2017 were compared to 1997–2003, improvements were noted in overall survival (P=0.0001 for 2004–2009 and P≤0.0001 for 2010–2017), progression-free survival (P=0.002 for 2004–2009 and P<0.0001 for 2010–2017), non-relapse mortality (P<0.0001 for 2004– 2009 and P<0.0001 for 2010–2017), and in rates of grades 2–4 acute and chronic graft-versus-host disease. For patients with hematologic malignancies who underwent transplantation with non-myeloablative conditioning, outcomes have improved during the past two decades. Trials reported are registered under clinicaltrials gov. Identifiers: NCT00003145, NCT00003196, 005803, NCT00006251, NCT00014235, NCT00027820, NCT00031655, NCT00036738, NCT00045435, NCT00052546, NCT00060424, NCT00075478, NCT00078858, NCT00089011, NCT00104858, NCT00105001, NCT00110058, NCT00397813, NCT00793572, NCT01231412, NCT01252667, NCT01527045. Fondazione Ferrata Storti 2020-06-04 /pmc/articles/PMC8168504/ /pubmed/32499241 http://dx.doi.org/10.3324/haematol.2020.248187 Text en Copyright© 2021 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Article Cooper, Jason P. Storer, Barry E. Granot, Noa Gyurkocza, Boglarka Sorror, Mohamed L. Chauncey, Thomas R. Shizuru, Judith Franke, Georg-Nikolaus Maris, Michael B. Boyer, Michael Bruno, Benedetto Sahebi, Firoozeh Langston, Amelia A. Hari, Parameswaran Agura, Edward D. Petersen, Søren Lykke Maziarz, Richard T. Bethge, Wolfgang Asch, Julie Gutman, Jonathan A. Olesen, Gitte Yeager, Andrew M. Hübel, Kai Hogan, William J. Maloney, David G. Mielcarek, Marco Martin, Paul J. Flowers, Mary E. D. Georges, George E. Woolfrey, Ann E. Deeg, H. Joachim Scott, Bart L. McDonald, George B. Storb, Rainer Sandmaier, Brenda M. Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades |
title | Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades |
title_full | Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades |
title_fullStr | Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades |
title_full_unstemmed | Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades |
title_short | Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades |
title_sort | allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168504/ https://www.ncbi.nlm.nih.gov/pubmed/32499241 http://dx.doi.org/10.3324/haematol.2020.248187 |
work_keys_str_mv | AT cooperjasonp allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT storerbarrye allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT granotnoa allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT gyurkoczaboglarka allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT sorrormohamedl allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT chaunceythomasr allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT shizurujudith allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT frankegeorgnikolaus allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT marismichaelb allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT boyermichael allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT brunobenedetto allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT sahebifiroozeh allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT langstonameliaa allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT hariparameswaran allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT aguraedwardd allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT petersensørenlykke allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT maziarzrichardt allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT bethgewolfgang allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT aschjulie allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT gutmanjonathana allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT olesengitte allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT yeagerandrewm allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT hubelkai allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT hoganwilliamj allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT maloneydavidg allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT mielcarekmarco allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT martinpaulj allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT flowersmaryed allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT georgesgeorgee allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT woolfreyanne allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT deeghjoachim allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT scottbartl allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT mcdonaldgeorgeb allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT storbrainer allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades AT sandmaierbrendam allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades |